MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial).
NCT: NCT07593261 · NOT_YET_RECRUITING
Brief Summary
This prospective phase II study evaluates the efficacy and safety of MRI-guided stereotactic body radiotherapy (MRIgSBRT) in patients with oligometastatic peritoneal carcinomatosis from gastrointestinal or gynecological tumors. Eligible patients with up to 5 MRI-visible peritoneal lesions and PCI ≤20 will be treated with MRIgSBRT using a hybrid MRI-linear accelerator with online adaptive planning and real-time tumor tracking. The primary endpoint is radiologic response rate according to RECIST 1.1 criteria. Secondary endpoints include overall survival, progression-free survival, local control, chemotherapy-free survival, and treatment-related toxicity. The study aims to assess MRIgSBRT as a safe and non-invasive treatment option for selected patients with limited peritoneal metastatic disease.
Frequently Asked Questions
What is MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial).?
MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial). is a clinical trial registered under NCT07593261. Current status: NOT_YET_RECRUITING.
What is the status of NCT07593261?
The current status of NCT07593261 (MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial).) is: NOT_YET_RECRUITING.
When did MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial). start?
MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial). started on 2026-07.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.